Mode
Text Size
Log in / Sign up

C-reactive protein-to-albumin ratio predicts 6-month major adverse limb events in hospitalized diabetic foot ulcer patientsOne Blood Test Could Save Diabetic Feet From Amputation

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that C-reactive protein-to-albumin ratio independently predicts 6-month major adverse limb events in diabetic foot ulcer patients.

This retrospective cohort study included 139 hospitalized patients with diabetic foot ulcers (DFUs) at a regional referral center in Northwest China. The primary outcome was 6-month major adverse limb events (MALE). The study compared a model incorporating the C-reactive protein-to-albumin ratio (CAR) against a base model using conventional clinical variables.

The analysis demonstrated that CAR was independently associated with MALE, with an adjusted odds ratio of 1.22 (95% confidence interval 1.03–1.48; P = 0.033). Additionally, log-transformed ulcer area was independently associated with MALE, showing an adjusted odds ratio of 2.43 (95% confidence interval 1.52–4.10; P < 0.001). In total, 43 patients (31.0%) experienced MALE during the 6-month follow-up period.

Regarding model performance, the inclusion of CAR achieved an AUC of 0.852 compared to 0.827 for the base model. However, the difference was not statistically significant by DeLong testing. Bootstrap validation yielded an optimism-corrected C-index of 0.831. Calibration remained acceptable. No adverse events, serious adverse events, discontinuations, or tolerability issues were reported as the study focused on risk prediction rather than intervention safety.

Key limitations include the need for external validation before broader clinical application. The modest incremental improvement in risk stratification suggests that while CAR adds predictive information, it should not be viewed as a definitive diagnostic marker without further confirmation in diverse populations.

Why foot sores need more than just looking

Doctors usually look at the wound size first. They measure how deep it is and how wide it spreads. But inflammation inside the body matters too.

A wound can look small on the surface. Yet, the body might be fighting a hard battle underneath. This hidden struggle can lead to bad outcomes even if the sore looks okay.

Inflammation is the body's way of fighting infection. But too much of it can damage healthy tissue. Doctors have known this for a long time.

Now, they have a new way to measure it. A specific blood test can show how much stress the body is under.

The hidden blood signal doctors missed

Think of the body like a house on fire. The smoke tells you the fire is bigger than the flames. A blood test can see that smoke before the damage spreads.

This test looks at two things in the blood. One part measures inflammation, like a smoke alarm. The other part measures nutrition, like the fuel supply.

When the inflammation is high and nutrition is low, the risk goes up. This combination is called the CAR score. It tells doctors if the body is struggling to heal.

Researchers looked at 139 patients in a hospital. They tracked results for six months to see what happened next. The goal was to find a better warning sign.

They checked the blood levels when the patients arrived. Then they watched to see who needed surgery or lost a limb.

High blood ratio meant higher risk of amputation. The model worked well to predict outcomes for these patients. It combined the blood test with the wound size.

The math showed a clear link between the ratio and danger. Patients with higher scores were much more likely to have major problems.

This included losing part of the leg or needing new blood vessels. It also included death related to the foot infection.

The tool helped doctors sort patients into risk groups. Those with high scores needed extra care right away. This helps teams treat the most serious cases first.

This does not mean you can order this test yourself today.

But there is a catch. The tool needs more testing before routine hospital use. It was only tested in one region so far.

Results from one place might not fit every hospital. Different patients and different care teams might react differently.

Experts say this adds valuable data to the mix. It helps doctors decide who needs extra care right away. This can change how teams treat serious wounds.

Why this test needs more proof first

Patients should talk to doctors about their blood work. Knowing the risk helps plan the best treatment path. It gives everyone a clearer picture of the future.

The group was small and from one location. This means the results might not fit every hospital. More data is needed to be sure.

The study was also done in the past. Medical care changes fast, so old data might not match today.

More studies will confirm if this works everywhere. Approval takes time to ensure safety for everyone. Research moves slowly but surely toward better care.

Doctors are excited about the potential. They want to use this tool to save limbs. But they must wait for the next round of checks.

This is a step forward in understanding diabetic feet. It shows that blood tests can tell us more than just infection. It shows the body's overall strength to heal.

For now, patients should focus on foot care. Keep wounds clean and check them every day. Talk to your doctor if you see any changes.

The future looks promising for better prediction. One day, this test might be standard for everyone. Until then, it remains a helpful new tool for experts.

Research takes time to make sure it works for all. But every small step brings us closer to saving limbs. This new ratio is a strong signal for the future.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
IntroductionDiabetic foot ulcers (DFUs) are associated with substantial risks of infection, amputation, and death; however, conventional anatomical classification systems do not fully capture the systemic inflammatory and nutritional status that may influence prognosis. We aimed to evaluate the prognostic value of the C-reactive protein-to-albumin ratio (CAR) and to develop a nomogram for predicting 6-month major adverse limb events (MALE) in hospitalized patients with DFUs.MethodsWe conducted a retrospective cohort study of patients treated at a regional referral center in Northwest China between January 2020 and January 2025. Among 321 screened patients, 139 with complete data were included in the final analysis. MALE was defined as major amputation, unplanned limb revascularization, or death related to foot deterioration or progression of sepsis. Multivariable logistic regression was used to identify independent predictors. Model performance was assessed by discrimination, calibration, bootstrap internal validation, the Brier score, integrated discrimination improvement, net reclassification improvement, and decision curve analysis.ResultsDuring follow-up, 43 patients (31.0%) experienced MALE. CAR (adjusted odds ratio 1.22, 95% confidence interval 1.03–1.48; P = 0.033) and log-transformed ulcer area (adjusted odds ratio 2.43, 95% confidence interval 1.52–4.10; P < 0.001) were independently associated with MALE. The model including CAR achieved an area under the receiver operating characteristic curve of 0.852, compared with 0.827 for the base model, although the difference was not statistically significant by DeLong testing. Adding CAR improved the Brier score and yielded a positive integrated discrimination improvement. Bootstrap validation showed an optimism-corrected C-index of 0.831, and calibration remained acceptable.DiscussionCAR was independently associated with 6-month MALE in patients with DFUs. A nomogram incorporating CAR and conventional clinical variables demonstrated good discrimination, calibration, and internal validity, with modest incremental improvement in risk stratification. External validation is warranted before broader clinical application.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.